Opus Genetics, Inc. (IRD)
Automate Your Wheel Strategy on IRD
With Tiblio's Option Bot, you can configure your own wheel strategy including IRD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IRD
- Rev/Share 0.3481
- Book/Share 0.213
- PB 4.6958
- Debt/Equity 0.0
- CurrentRatio 3.2413
- ROIC -2.4279
- MktCap 59661200.0
- FreeCF/Share -0.81
- PFCF -2.3327
- PE -0.5488
- Debt/Assets 0.0
- DivYield 0
- ROE -1.8019
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IRD | Craig Hallum | -- | Buy | -- | $6 | April 11, 2025 |
News
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a condition with no current FDA-approved therapies Safety profile consistent with previous studies, with no new safety signals identified No evidence of tachyphylaxis was observed in this study over the 6-week period Study was conducted under FDA Special Protocol Assessment and Fast-Track Designation RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage …
Read More
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.29 per share a year ago.
Read More
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders, today announced presentations related to its IRD gene therapy programs at these upcoming scientific conferences in May.
Read More
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
Published: March 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances will be delivered this week at World Cornea Congress IX, taking place March 20-22, 2025 in Washington, D.C.
Read More
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
Published: March 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Additional approximately $21 million tied to data release for the Company's BEST1 program Additional approximately $21 million tied to data release for the Company's BEST1 program
Read More
Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision Enrollment completion in LYNX-2 pivotal Phase 3 trial expected in first half of 2025 Enrollment now complete in VEGA-3 pivotal Phase 3 trial evaluating Phentolamine Ophthalmic Solution 0.75% for presbyopia DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, today announced completion of enrollment in the VEGA-3 Phase 3 clinical trial …
Read More
About Opus Genetics, Inc. (IRD)
- IPO Date 2015-01-19
- Website https://opusgtx.com
- Industry Biotechnology
- CEO Mr. George Magrath M.B.A., M.D., M.S.
- Employees 18